Search Results

You are looking at 1 - 10 of 200 items for :

  • "cetuximab" x
  • Refine by Access: All x
Clear All
Full access

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister

The epidermal growth factor receptor (EGFR) is expressed on virtually all head and neck squamous cell cancer (HNSCC) tumors, and high levels of expression have been associated with unfavorable clinical prognosis. 1 , 2 Cetuximab is a chimeric IgG

Full access

Safety and Efficacy of FOLFOX Followed by Cetuximab for Metastatic Colorectal Cancer With Severe Liver Dysfunction

Raymond Elsoueidi, Jessica Craig, Hesham Mourad, and Elie M. Richa

dysfunction Discuss what is known regarding the safety and efficacy of FOLFOX in the treatment of patients with mCRC and severe liver dysfunction Evaluate available data regarding the safety of cetuximab monotherapy for the treatment of mCRC in patients

Full access

Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers

Presented by: Maura L. Gillison

trials shows that cetuximab significantly compromises locoregional tumor control and overall survival compared with cisplatin, without reducing overall toxicity events. Of note, research has shown that cisplatin appears to be important for locoregional

Full access

Current Recommendations for Systemic Therapy of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury and David G. Pfister

agents in the management of R/M HNSCC Analyze the use of cetuximab in the management of R/M HNSCC General Considerations and Prognostic Factors For patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) who are considered

Full access

The Role of Inhibitors of the Epidermal Growth Factor in Management of Head and Neck Cancer

Bruce Brockstein, Mario Lacouture, and Mark Agulnik

Edited by Kerrin G. Robinson

. Cancer Res 1993 ; 53 : 3579 – 3584 . 24. Imai K Takaoka A . Comparing antibody and small-molecule therapies for cancer . Nat Rev Cancer 2006 ; 6 : 714 – 727 . 25. Kawaguchi Y Kono K Mimura K . Cetuximab induce antibody

Full access

Chemotherapy for Metastatic Colorectal Cancer

Joseph Rosales and Lucille A. Leong

. 18 Tournigand C Andre T Achille E . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study . J Clin Oncol 2004 ; 22 : 229 – 237 . 19 Cunningham D Humblet Y Siena S . Cetuximab

Full access

QIM24-181: Joining Forces to Minimize Hypomagnesemia in Patients Receiving Cisplatin and Cetuximab Infusions

Janice DallaCosta, Patrick Skeffington, and Ny Tran

Background: Cisplatin and cetuximab can cause hypomagnesemia thought to be related injury to the ascending limb of the loop of Henle where the majority of magnesium is reabsorbed. This injury can occur as much as six years after treatment is

Full access

Controversies in the Locoregional Management of Head and Neck Cancer

David M. Brizel, William Lydiatt, and A. Dimitrios Colevas

, elimination of cisplatin-based concurrent systemic therapy, use of alternative systemic agents such as cetuximab, or an increased reliance on primary surgical therapy instead of (chemo)radiation have all been proposed. The crux of the debate is whether

Full access

Biologics in Cervical Cancer Therapy

Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk

adverse events being gastrointestinal, fatigue, and rash. The authors concluded that erlotinib was inactive as monotherapy in patients with recurrent squamous cell carcinoma of the uterine cervix. 30 Cetuximab is another drug targeting EGFR that has been

Full access

CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series

Mark Joshua Chang, Wolfram Samlowski, Douglas Fife, Mac Machan, and Raul Meoz

tolerated. Most laCSCC tumors express high levels of epidermal growth factor receptors (EGFR). Cetuximab has shown activity in other EGFR expressing cancers and enhances the effectiveness of radiotherapy. Methods: We performed a retrospective review of